{
  "id": 7785831,
  "title": "Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder",
  "url": "https://urgent.news/2026/09/16/optimi-health-expands-clinical-program-with-phase-3-trial-evaluating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T12:27:47.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/optimi-health-expands-clinical-program-with-phase-3-trial-evaluating-mdma-assisted-therapy-for-post-traumatic-stress-disorder"
  },
  "original_language": "en",
  "account": null,
  "summary": "Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}